Álvarez ALJ

Language: Spanish
References: 16
Page: 2-7
PDF size: 154.95 Kb.

ABSTRACT

Inside the classification of the Inflammatory bowel diseaseswe can find the ulcerative colitis and the Crohn´s disease, both of themhave a high worldwide incidence. Up today the treatments for these diseases are inefficient due to the lack of knowledge of its pathogenesis. Most of the therapies increase malaise to the patient. Lactic bacteria are classified as probiotics and they have been used as expression models for heterologous proteins. Lactococcus lactis is one of the most studied because of its high capacity to secrete heterologous proteins to the media; this gives it a great value to use it for developing therapeutic vaccines of easy administration ping therapeutic vaccines of easy administration.

REFERENCES

1. DignassAU, Baumgart DC, SturmA(2004) Review article: the aetiopathogenesis of inflammatory bowel disease- immunology and repair mechanisms. Aliment Pharmacol Ther 20:9-17.

2. Hanauer SB (2006) Inflammatory bowel disease: Epidemiology, pathogenesis and therapeutic opportunities. Inflamm Bowel Dis 12(1):S3- S9.

3. Shanahan F (2004) Probiotics in inflammatory bowel disease- therapeutic rationale and role. Adv Drug Deliv Rev 56:809-818.

4. Steidler L (2001) Microbiological and immunological strategies for treatment of inflammatory bowel disease. Microbes Infect 3:1157-1166.

5. Caprilli R, Viscido A, Guagnozzi D (2002) Review article: biological agents in the treatment of Crohn´s disease. Aliment Pharmacol Ther 16:1579-1590.

6. LimWC, Hanauer SB (2004) Emerging biologic therapies in inflammatory bowel disease. Rev Gastroenterol Disord 4(2):66-85.

7. Papachristou GI, Plevy S (2004) Novel biologics in inflammatory bowel disease. Gastroenterol Clin N Am 33:251-269.

8. Strober W, Fuss JM, Blumberg RS (2002) The immunology of mucosal models of inflammation. Annu Rev Immunol 20:495-549.

9. Kopp-Hoolihan L (2001) Prophylactic and therapeutic uses of probiotics: a review. JAmDietAssoc 101:229-241.

10. Rolfe RD (2000) The role of probiotic cultures in the control of gastrointestinal health. J Nutr 130:396S-402S.

11. O´Mahony L, Sheil B, Shanahan F (2007) Probiotic effects on inflammatory bowel disease. J Nutr 137:819S- 824S.

12. Langella P,Cortes-PerezNG, Lefevre F,Corthier G,Adel- Patient K, Bermudez-Humarán LG (2007) Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria. Vaccine 25:6581-6588.

13. Le LoirY,Azevedo V, Oliveira SC, Freitas DA,Miyoshi A, Bermúdez-Humarán LG, Nouaille S, Ribeiro LA, Leclercq S, Gabriel JE, Guimaraes VD, Oliveira MN, Charlier C, Gautier M, Langella P (2005) Protein secretion in Lactococcus lactis: an efficient way to increase the overall heterologous protein production. Microbial cell factories. http://www.microbialcellfactories.com/ content/4/1/2 [revisado el 17 de febrero de 2007].

14. Wells JM,MercenierA(2008)Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 6:349-362.

15. Lee P, Faubert GM (2006) Expression of the Giardia lamblia cyst wall protein 2 in Lactococcus lactis. Microbiol 152:1981-1990.

16. Alonso S, Sim ACN, Lin W, Tan GKX, Sim MST, Chow VTK (2008) Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen. Vaccine 26:1145- 1154.